Drug Trial Radar · NCT07232602
KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04)
Last checked: Nov 19, 2026Latest source record: Oct 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
55
Planned (sponsor's estimate)
Start
Feb 9, 2026
Primary completion
Jul 8, 2031
Study completion Jul 8, 2031
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Nov 18, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Researchers are looking for new ways to treat people with urothelial cancer (UC) that is locally advanced or metastatic. The standard treatment for locally advanced or metastatic UC is enfortumab vedotin (EV) given with pembrolizumab. The goals of this study are to learn about: * The safety of the study treatment when given with standard treatment and if people tolerate it * The number of people who have the cancer respond (cancer gets smaller or goes away) with the new study treatment when given with standard treatment.
Conditions
- Bladder Cancer
Interventions
MK-3120Drug
Administered via intravenous (IV) infusion on day 1 and day 8 of each 3-week cycle
EVDrug
Administered via IV infusion on day 1 and day 8 of each 3-week cycle
PembrolizumabBiological
Administered via IV infusion on day 1 of each 3-week cycle
Rescue MedicationDrug
Participants receive rescue medication at the investigator's discretion, per approved product label. Recommended rescue medication is Granulocyte Colony-Stimulating Factor (G-CSF).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants Who Experience an Adverse Event (AE)Time frame: Up to approximately 27 months
- Number of Participants Who Experience a Dose Limiting Toxicity (DLT)Time frame: Up to approximately 21 days
- Number of Participants Who Discontinue Study Treatment Due to an AETime frame: Up to approximately 24 months
- Objective Response Rate (ORR) as Assessed by InvestigatorTime frame: Up to approximately 58 months
Locations
17 sites in 8 countries. Site status is shown where the registry gives one.
UCSF Medical Center at Mission Bay ( Site 5044)
San Francisco, California · Recruiting
University of Chicago Medical Center ( Site 5037)
Chicago, Illinois · Recruiting
Memorial Sloan Kettering Cancer Center ( Site 5031)
New York, New York · Recruiting
Cleveland Clinic Taussig Cancer ( Site 5036)
Cleveland, Ohio · Recruiting
Huntsman Cancer Institute ( Site 5041)
Salt Lake City, Utah · Recruiting
Fundación Arturo López Pérez ( Site 5151)
Santiago, Region M. de Santiago, Chile · Recruiting
CHU de Bordeaux Hop St ANDRE ( Site 5607)
Bordeaux, Gironde, France · Recruiting
Rambam Health Care Campus ( Site 5501)
Haifa, Israel · Recruiting
Rabin Medical Center ( Site 5504)
Petah Tikva, Israel · Recruiting
Nederlands Kanker Instituut Antoni van Leeuwenhoek (NKI AVL) ( Site 5302)
Amsterdam, North Holland, Netherlands · Recruiting
Erasmus MC ( Site 5303)
Rotterdam, South Holland, Netherlands · Recruiting
Severance Hospital, Yonsei University Health System ( Site 5903)
Seoul, South Korea · Recruiting
Asan Medical Center ( Site 5901)
Seoul, South Korea · Recruiting
Samsung Medical Center ( Site 5902)
Seoul, South Korea · Recruiting
Hospital Universitari Vall de Hebron ( Site 5767)
Barcelona, Spain · Recruiting
Hospital Clinico San Carlos ( Site 5765)
Madrid, Spain · Recruiting
St Bartholomew s Hospital ( Site 5206)
London, London, City of, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.